Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more
Combigene AB (COMBI) - Net Assets
Latest net assets as of December 2024: Skr71.58 Million SEK
Based on the latest financial reports, Combigene AB (COMBI) has net assets worth Skr71.58 Million SEK as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr75.88 Million) and total liabilities (Skr4.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr71.58 Million |
| % of Total Assets | 94.33% |
| Annual Growth Rate | 57.9% |
| 5-Year Change | 0.2% |
| 10-Year Change | 597.28% |
| Growth Volatility | 235.69 |
Combigene AB - Net Assets Trend (2012–2024)
This chart illustrates how Combigene AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Combigene AB (2012–2024)
The table below shows the annual net assets of Combigene AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr71.58 Million | -38.54% |
| 2023-12-31 | Skr116.46 Million | -23.45% |
| 2022-12-31 | Skr152.12 Million | -3.89% |
| 2021-12-31 | Skr158.28 Million | +121.58% |
| 2020-12-31 | Skr71.43 Million | +251.80% |
| 2019-12-31 | Skr20.30 Million | -0.74% |
| 2018-12-31 | Skr20.46 Million | +214.11% |
| 2017-12-31 | Skr6.51 Million | +59.63% |
| 2016-12-31 | Skr4.08 Million | -60.26% |
| 2015-12-31 | Skr10.27 Million | +81.20% |
| 2014-12-31 | Skr5.67 Million | +846.43% |
| 2013-12-31 | Skr598.60K | +100.81% |
| 2012-12-31 | Skr298.09K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Combigene AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4477609300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr990.00K | 1.38% |
| Other Components | Skr115.47 Million | 161.31% |
| Total Equity | Skr71.58 Million | 100.00% |
Combigene AB Competitors by Market Cap
The table below lists competitors of Combigene AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aferian Plc
PINK:AOECF
|
$3.61 Million |
|
Secos Group Ltd
AU:SES
|
$3.61 Million |
|
PLYTEC Holding Berhad
KLSE:0289
|
$3.61 Million |
|
Boutique Corporation Public Company Limited
BK:BC
|
$3.61 Million |
|
Kesla Oyj A
HE:KELAS
|
$3.61 Million |
|
GPO Plus Inc
OTCQB:GPOX
|
$3.61 Million |
|
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk PT
JK:JMAS
|
$3.61 Million |
|
Africa Energy Corp
PINK:HPMCF
|
$3.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Combigene AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 116,456,699 to 71,579,000, a change of -44,877,699 (-38.5%).
- Net loss of 44,878,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-44.88 Million | -62.7% |
| Other Changes | Skr301.00 | +0.0% |
| Total Change | Skr- | -38.54% |
Book Value vs Market Value Analysis
This analysis compares Combigene AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 169.34x to 0.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.01 | Skr2.46 | x |
| 2013-12-31 | Skr2.08 | Skr2.46 | x |
| 2014-12-31 | Skr12.81 | Skr2.46 | x |
| 2015-12-31 | Skr19.47 | Skr2.46 | x |
| 2016-12-31 | Skr3.80 | Skr2.46 | x |
| 2017-12-31 | Skr7.96 | Skr2.46 | x |
| 2018-12-31 | Skr14.74 | Skr2.46 | x |
| 2019-12-31 | Skr6.22 | Skr2.46 | x |
| 2020-12-31 | Skr7.74 | Skr2.46 | x |
| 2021-12-31 | Skr9.14 | Skr2.46 | x |
| 2022-12-31 | Skr7.68 | Skr2.46 | x |
| 2023-12-31 | Skr5.88 | Skr2.46 | x |
| 2024-12-31 | Skr3.61 | Skr2.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Combigene AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13766.26%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-62.70%) is below the historical average (-55.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -3.96% | 0.00% | 0.00x | 1.99x | Skr-41.62K |
| 2013 | -4.59% | 0.00% | 0.00x | 1.07x | Skr-87.35K |
| 2014 | -16.96% | 0.00% | 0.00x | 1.10x | Skr-1.53 Million |
| 2015 | -63.02% | 0.00% | 0.00x | 1.07x | Skr-7.50 Million |
| 2016 | -212.43% | 0.00% | 0.00x | 1.20x | Skr-9.07 Million |
| 2017 | -137.56% | -298.60% | 0.37x | 1.25x | Skr-9.61 Million |
| 2018 | -64.27% | -161379.82% | 0.00x | 1.72x | Skr-15.19 Million |
| 2019 | -96.61% | -119.04% | 0.34x | 2.37x | Skr-19.69 Million |
| 2020 | -43.08% | -284.22% | 0.14x | 1.11x | Skr-37.92 Million |
| 2021 | 13.25% | 24.95% | 0.51x | 1.05x | Skr5.14 Million |
| 2022 | -4.05% | -23.06% | 0.17x | 1.04x | Skr-21.37 Million |
| 2023 | -30.63% | -643.31% | 0.05x | 1.04x | Skr-47.31 Million |
| 2024 | -62.70% | -13766.26% | 0.00x | 1.06x | Skr-52.04 Million |
Industry Comparison
This section compares Combigene AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Combigene AB (COMBI) | Skr71.58 Million | -3.96% | 0.06x | $3.61 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |